作者:Xiaobing Li、William V Murray、Linda Jolliffe、Virginia Pulito
DOI:10.1016/s0960-894x(00)00169-4
日期:2000.5
A novel series of arylpiperazines has been synthesized and identified as antagonists of alpha(1a) adrenergic receptor (alpha(1a)-AR) implicated in benign prostatic hyperplasia. These compounds selectively bind to membrane bound alpha(1a)-AR with K(i)s as low as 0.66 nM. As such, these potentially represent a viable treatment for BPH without the side effects associated with known alpha(1)-adrenergic antagonists. (C) 2000 Elsevier Science Ltd. All rights reserved.